You are here

KRONİK BÖBREK YETMEZLİĞİNDE PANSİTOPENİNİN SEYREK GÖRÜLEN BİR NEDENİ : MYELODİSPLASTİK SENDROM (OLGU SUNUMU)

Share
A RARE CAUSE OF PANCYTOPENIA IN A PATIENT WITH END-STAGE RENAL DISEASE : MYELODYSPLASTIC SYNDROME (A CASE REPORT)

Journal Name:

FULL TEXT (PDF): 

Volume:

Publication Year:

Number:

Sayfa Aralığı:: 
112-115

Publication Language:

Abstract (Original Language): 
Miyelodisplastik sendrom (MDS) klonal kök hücreden köken alan, genellikle erişkinleri etkileyen heterojen grup bir hastalıktır. KBY'inde MDS seyrek görülmektedir. Bu makalede yaklaşık iki yıldır KBY nedeni ile Ünitemizde düzenli olarak hemodiyalize giren, dokuz aydır da, yapılan tetkikler neticesinde pansitopeni saptanan 38 yaşındaki bayan olgu sunulmuştur. Olgumuz yaklaşık dokuz aydır destek tedavi ile hayatını sürdürmektedir. Sonuç olarak MDS saptanan KBY olgularında immünsupressif ve sitotoksik tedavi yerine destek tedavisi tercih edilmelidir.
Abstract (2. Language): 
Myelodysplasia syndromes (MDS) are a heterogenous group of clonal stem cell disorders which generally occur in adults. MDS are rare seen in patients with end-stage renal disease (ESRD). In this study, we presents a 38-year-old woman with ESRD who had regularly received hemodialysis therapy for two years. In this patient, we observed pancytopenia and the patient who survived for nine months by supportive therapy. In conclusion, supportive therapy should be prefered in MDS' patients with ESRD.

REFERENCES

References: 

1. Schmitt-Graeff A, Mattern D, Köhler H, Hezel J, Lübbert
M. Myelodysplastic syndromes (MDS). Aspects of hematopathologic diagnosis. Pathol 2000; 21:1-15.
2. Gordon MS. Advances in supportive care of myelodysplatic syndrome. Semin Hematol 1999; 36
(Suppl6):21-24.
3. Skorecki K, Green J, Brenner BM. Chronic renal failure in : Braunwald E, Fauci AS, Kasper DL, et al (eds). Harrison's Principles of Internal Medicine. McGraw-Hill Co, London 2001:1551-1561.
4. Besarab A, Schmidt R. Anemia in patients with end-stage renal disease, in: Nissenson AR, Fine RN, et al (eds). Dialysis Threapy, 3rd edition, Hanley & Belfus Inc, Philadelphia 2002;309-313.
5. Van Wyck DB. Management of early renal anaemia: diagnostic work-up, iron therapy, epoetin therapy. Nephrol Dial Transplant 2000;15(Suppl 3):36-39.
6. Altieri P, Sau G, Cao R, et al. Immunsupressive treatment in dialysis patients. Nephrol Dial Transplant 2002;17
(Suppl l):2-9.
7. Young S. Aplastic anemia, myelodysplasia, and related bone marrow failure syndromes in: Braunwald E, Fauci AS, Kasper DL, et al (eds). Harrison's Principles of Internal
Medicine. McGraw-Hill Co, London 2001 ;692-700.
8. Hamblin T. Clinical features of MDS. Leuk Res 1992; 16
(Suppl l):89-93.
9. Tennant GB, Al-Sabah Al, Burnett AK. Prognosis of myelodysplasic patients: non-parametric multiple regression analysis of populations stratified by mean corpuscular volume and marrow myeloblast number. Br J Haematol 2002; 119 (Suppl l):87-96.
10. Hasle MA, Wadsworth LD, Masssing BG, et al. A
population based study of childhood myelodysplastic syndrome in British Columbia, Canada. Br J Hematol 1999;8:347-353.
11. Sueiu S, Kuse R, Weh HJ, et al. Results of chromosome studies and their relation to morphology, course and prognosis in 120 patients with de novo myelodysplastic syndrome. Cancer Cytogenet 1990;44:15-26.
12. Dunn CJ, Wagstaff AJ, Epoetin alfa. A review of its clinical
efficacy in the management of anaemia associated with renal failure and chronic disease and its use in surgical patients. Drugs Aging 1995; 7 (Suppl 2):131-156. Salvati F, Liani M, Bonomini M. Response to recombinant human erythropoietin (rHu-Epo) in a patient with chronic renal failure and myelomocytic
leukaemia. Nephrol Dial Transplant 2001;16:191-192
115

Thank you for copying data from http://www.arastirmax.com